- Home
- ITOS vs MYGN Comparison
ITOS vs MYGN Comparison
Compare ITOS & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITOS
- MYGN
- Stock Information
- Founded
- ITOS 2011
- MYGN 1991
- Country
- ITOS United States
- MYGN United States
- Employees
- ITOS N/A
- MYGN N/A
- Industry
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ITOS Health Care
- MYGN Health Care
- Exchange
- ITOS Nasdaq
- MYGN Nasdaq
- Market Cap
- ITOS 450.9M
- MYGN 423.1M
- IPO Year
- ITOS 2020
- MYGN 1995
- Fundamental
- Price
- ITOS N/A
- MYGN $6.61
- Analyst Decision
- ITOS Hold
- MYGN Hold
- Analyst Count
- ITOS 6
- MYGN 13
- Target Price
- ITOS $10.40
- MYGN $13.50
- AVG Volume (30 Days)
- ITOS 1.6M
- MYGN 1.5M
- Earning Date
- ITOS 08-06-2025
- MYGN 11-06-2025
- Dividend Yield
- ITOS N/A
- MYGN N/A
- EPS Growth
- ITOS N/A
- MYGN N/A
- EPS
- ITOS N/A
- MYGN N/A
- Revenue
- ITOS N/A
- MYGN $832,900,000.00
- Revenue This Year
- ITOS N/A
- MYGN $0.17
- Revenue Next Year
- ITOS N/A
- MYGN $6.19
- P/E Ratio
- ITOS N/A
- MYGN N/A
- Revenue Growth
- ITOS 177.89
- MYGN 3.83
- 52 Week Low
- ITOS $4.80
- MYGN $3.76
- 52 Week High
- ITOS $17.63
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- ITOS 1.63
- MYGN 64.60
- Support Level
- ITOS $10.10
- MYGN $5.78
- Resistance Level
- ITOS $10.17
- MYGN $7.05
- Average True Range (ATR)
- ITOS 0.03
- MYGN 0.34
- MACD
- ITOS -1.20
- MYGN 0.07
- Stochastic Oscillator
- ITOS 0.00
- MYGN 75.82
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.